Evofem Biosciences, Inc.

EVFM

US30048L3024

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 15:58:47 2024-07-17 EDT			5-day change	1st Jan Change
0.0109 ^USD	+4.31%		+9.00%	-82.97%

07-17	Aditxt Soars After Amendment of Evofem Merger Terms	MT
07-17	Top Premarket Gainers	MT

Evofem Biosciences, Inc. announced that it has received $20 million in funding from Invesco Ltd.

January 16, 2018

On January 17, 2018, Evofem Biosciences, Inc. (NasdaqCM:EVFM) closed the transaction. The transaction saw participation from returning investor Invesco Ltd. (NYSE:IVZ).

Latest news about Evofem Biosciences, Inc.

Aditxt Soars After Amendment of Evofem Merger Terms	07-17	MT
Top Premarket Gainers	07-17	MT
Lupin Sells US Commercial Women's Health Specialty Business to Evofem Biosciences	07-16	MT
Evofem Bio.sciences, Inc. acquired Womens Health Specialty Business of Lupin Limited for $84 million.	07-14	CI
Transcript : Evofem Biosciences, Inc. - Special Call	05-15
Evofem Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Evofem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Evofem Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-27	CI
Transcript : Evofem Biosciences, Inc. - Special Call	03-26
North American Morning Briefing : Dow Set For New -2-	12-14	DJ
Laidlaw Downgrades Evofem Biosciences to Hold From Buy	12-13	MT
Evofem Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Transcript : Evofem Biosciences, Inc. Presents at Virtual Investor Ask the CEO Conference, Oct-24-2023 10:00 AM	23-10-24
Evofem Biosciences, Inc. Provides Sales Guidance for the Third Quarter of 2023	23-10-24	CI
Evofem Biosciences, Inc. announced that it has received $3.504807 million in funding	23-09-26	CI
North American Morning Briefing : Treasury Yields Keep Pushing Higher	23-08-17	DJ
Evofem Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Evofem Biosciences, Inc. announced that it has received $0.65 million in funding	23-08-03	CI
Evofem Biosciences, Inc. announced that it has received $1.5 million in funding	23-07-02	CI
North American Morning Briefing : Recession Threat Grows as Further Tightening Likely	23-06-23	DJ
Evofem Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-16	CI
North American Morning Briefing : Stock Futures -2-	23-06-16	DJ
MEI Pharma's Finance Chief Brian Drazba to Step Down; Company Names Justin File as Successor	23-06-13	MT
MEI Pharma Names Justin File as Chief Financial Officer	23-06-13	MT
Evofem Biosciences, Inc. Receives Paragraph IV Certification Notice Letter from Padagis Israel Pharmaceuticals Ltd	23-05-05	CI

Chart Evofem Biosciences, Inc.

Duration

Period

More charts

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. It is commercializing advanced products to address unmet needs in womenâs sexual and reproductive health. Its first FDA-approved product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Phexxi is an advanced gel that works to prevent pregnancy without the use of hormones. Phexxi prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Phexxi is designed to address underserved and unmet needs in the birth control market. Using its platform, women can have a telehealth visit with a health care provider to determine their eligibility for a Phexxi prescription. It is also focused on commercializing SOLOSEC (secnidazole) 2g oral granules that address two pervasive sexual health infections.

Sector

Pharmaceuticals

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.0109

Average target price

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EVOFEM BIOSCIENCES, INC.	-82.97%	968K
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+32.07%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+16.15%	247B
NOVARTIS AG	+14.52%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals